Clinical trial · no report yet · Phase 2
NCT05112601
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05112601 ↗
- Recruiting
- National Cancer Institute (NCI)
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Carcinoma
- Interventions
- Biospecimen Collection; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Arms
- Arm I (nivolumab and ipilimumab) · Experimental
- Arm II (nivolumab) · Active comparator
- Enrollment
- 81 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jun 2, 2022
- Primary completion
- Jul 30, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT05112601 · updated Oct 9, 2026